[^1]
| RAG2 Protein |
|---|
| Gene | [RAG2](/genes/rag2) (Recombination Activating 2) |
| UniProt ID | [P55895](https://www.uniprot.org/uniprot/P55895) |
| PDB Structures | 1R3J, 2V27 |
| Molecular Weight | ~ 131 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | RAG1/2 recombinase complex |
is a protein encoded by the RAG2 gene that rag2 functions as the essential cofactor for rag1 in v(d)j recombination during lymphocyte development. in the nervous system:. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
RAG2 is a 131 kDa protein that forms a heterodimeric complex with RAG1 to mediate V(D)J recombination. Key structural features include:
- PHD finger domain - C-terminal plant homeodomain that binds histone H3K4me3, regulating recombination activity
- ** acidic region** - N-terminal acidic domain that interacts with RAG1 and other cofactors
- High-mobility group (HMG) box - Bends DNA to facilitate synapsis of recombination signal sequences
- C-terminal nonamer-binding region - Works with RAG1 to recognize the RSS nonamer
RAG2 functions as the essential cofactor for RAG1 in V(D)J recombination during lymphocyte development. In the nervous system:
- Chromatin accessibility: RAG2's PHD finger senses histone marks to target recombination to open chromatin
- DNA damage response: RAG2 interacts with ATM and other DNA repair proteins
- Epigenetic regulation: RAG2 associates with histone modifiers
- RAG2-mediated DNA damage responses may contribute to neuronal loss in AD
- Aberrant V(D)J-like recombination events could generate genomic instability
- RAG2 expression altered in AD brain regions
- DNA repair defects in dopaminergic neurons may involve RAG2 dysregulation
- Cell cycle re-entry mechanisms linked to RAG2 activity
- RAG2 expression changes in motor neurons in ALS models
- Genomic instability from RAG2 activity may contribute to TDP-43 pathology
- RAG2 inhibitors: Being explored for autoimmune conditions
- Histone mimicry: Therapeutic strategies targeting the PHD finger
- DNA damage modulators: PARP and ATM inhibitors to mitigate DNA damage